Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters
High Glutaminase (GLS1) expression may have prognostic implications in colorectal and breast cancers; however, high quality data for expression in prostate cancer (PCa) are lacking. The purpose of this study is to investigate the status of GLS1 expression in PCa and correlated expression levels with...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/9/2157 |
| _version_ | 1797535710351196160 |
|---|---|
| author | Zin W. Myint Ramon C. Sun Patrick J. Hensley Andrew C. James Peng Wang Stephen E. Strup Robert J. McDonald Donglin Yan William H. St. Clair Derek B. Allison |
| author_facet | Zin W. Myint Ramon C. Sun Patrick J. Hensley Andrew C. James Peng Wang Stephen E. Strup Robert J. McDonald Donglin Yan William H. St. Clair Derek B. Allison |
| author_sort | Zin W. Myint |
| collection | DOAJ |
| description | High Glutaminase (GLS1) expression may have prognostic implications in colorectal and breast cancers; however, high quality data for expression in prostate cancer (PCa) are lacking. The purpose of this study is to investigate the status of GLS1 expression in PCa and correlated expression levels with clinicopathologic parameters. This study was conducted in two phases: an exploratory cohort analyzing RNA-Seq data for GLS1 from The Cancer Genome Atlas (TCGA) data portal (246 PCa samples) and a GLS1 immunohistochemical protein expression cohort utilizing a tissue microarray (TMA) (154 PCa samples; 41 benign samples) for correlation with clinicopathologic parameters. In the TCGA cohort, GLS1 mRNA expression did not show a statistically significant difference in disease-free survival (DFS) but did show a small significant difference in overall survival (OS). In the TMA cohort, there was no correlation between GLS1 expression and stage, Gleason score, DFS and OS. GLS1 expression did not significantly correlate with the clinical outcomes measured; however, GLS1 expression was higher in PCa cells compared to benign epithelium. Future studies are warranted to evaluate expression levels in greater numbers of high-grade and advanced PCa samples to investigate whether there is a rational basis for GLS1 targeted therapy in a subset of patients with prostate cancer. |
| first_indexed | 2024-03-10T11:49:17Z |
| format | Article |
| id | doaj.art-8091525d917a408392b7350060ebfe42 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T11:49:17Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8091525d917a408392b7350060ebfe422023-11-21T17:50:25ZengMDPI AGCancers2072-66942021-04-01139215710.3390/cancers13092157Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic ParametersZin W. Myint0Ramon C. Sun1Patrick J. Hensley2Andrew C. James3Peng Wang4Stephen E. Strup5Robert J. McDonald6Donglin Yan7William H. St. Clair8Derek B. Allison9Department of Internal Medicine, Division of Medical Oncology, University of Kentucky, Lexington, KY 40536, USAMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USADepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USADepartment of Internal Medicine, Division of Medical Oncology, University of Kentucky, Lexington, KY 40536, USAMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USADepartment of Pathology and Laboratory Medicine, University of Kentucky, Lexington KY 40536, USAMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USAMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USAMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USAHigh Glutaminase (GLS1) expression may have prognostic implications in colorectal and breast cancers; however, high quality data for expression in prostate cancer (PCa) are lacking. The purpose of this study is to investigate the status of GLS1 expression in PCa and correlated expression levels with clinicopathologic parameters. This study was conducted in two phases: an exploratory cohort analyzing RNA-Seq data for GLS1 from The Cancer Genome Atlas (TCGA) data portal (246 PCa samples) and a GLS1 immunohistochemical protein expression cohort utilizing a tissue microarray (TMA) (154 PCa samples; 41 benign samples) for correlation with clinicopathologic parameters. In the TCGA cohort, GLS1 mRNA expression did not show a statistically significant difference in disease-free survival (DFS) but did show a small significant difference in overall survival (OS). In the TMA cohort, there was no correlation between GLS1 expression and stage, Gleason score, DFS and OS. GLS1 expression did not significantly correlate with the clinical outcomes measured; however, GLS1 expression was higher in PCa cells compared to benign epithelium. Future studies are warranted to evaluate expression levels in greater numbers of high-grade and advanced PCa samples to investigate whether there is a rational basis for GLS1 targeted therapy in a subset of patients with prostate cancer.https://www.mdpi.com/2072-6694/13/9/2157glutaminaseimmunohistochemistryin situ methodsprostateprognosis |
| spellingShingle | Zin W. Myint Ramon C. Sun Patrick J. Hensley Andrew C. James Peng Wang Stephen E. Strup Robert J. McDonald Donglin Yan William H. St. Clair Derek B. Allison Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters Cancers glutaminase immunohistochemistry in situ methods prostate prognosis |
| title | Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters |
| title_full | Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters |
| title_fullStr | Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters |
| title_full_unstemmed | Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters |
| title_short | Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters |
| title_sort | evaluation of glutaminase expression in prostate adenocarcinoma and correlation with clinicopathologic parameters |
| topic | glutaminase immunohistochemistry in situ methods prostate prognosis |
| url | https://www.mdpi.com/2072-6694/13/9/2157 |
| work_keys_str_mv | AT zinwmyint evaluationofglutaminaseexpressioninprostateadenocarcinomaandcorrelationwithclinicopathologicparameters AT ramoncsun evaluationofglutaminaseexpressioninprostateadenocarcinomaandcorrelationwithclinicopathologicparameters AT patrickjhensley evaluationofglutaminaseexpressioninprostateadenocarcinomaandcorrelationwithclinicopathologicparameters AT andrewcjames evaluationofglutaminaseexpressioninprostateadenocarcinomaandcorrelationwithclinicopathologicparameters AT pengwang evaluationofglutaminaseexpressioninprostateadenocarcinomaandcorrelationwithclinicopathologicparameters AT stephenestrup evaluationofglutaminaseexpressioninprostateadenocarcinomaandcorrelationwithclinicopathologicparameters AT robertjmcdonald evaluationofglutaminaseexpressioninprostateadenocarcinomaandcorrelationwithclinicopathologicparameters AT donglinyan evaluationofglutaminaseexpressioninprostateadenocarcinomaandcorrelationwithclinicopathologicparameters AT williamhstclair evaluationofglutaminaseexpressioninprostateadenocarcinomaandcorrelationwithclinicopathologicparameters AT derekballison evaluationofglutaminaseexpressioninprostateadenocarcinomaandcorrelationwithclinicopathologicparameters |